Institut Claudius Regaud

corporate_fareorganization

Institut Claudius Regaud

- Funding / Projects
  (74)

74 Projects, page 1 of 15

Prospective construction and validation of a prognostic score to idendify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival.
assignment_turned_inProjectPartners:Institut de Cancérologie de l'Ouest, Centre Georges-François Leclerc, Hôpital Morvan, Hôpital de Rangueil, Centre Eugène Marquis +3 partners
Institut de Cancérologie de l'Ouest,
Centre Georges-François Leclerc,
Hôpital Morvan,
Hôpital de Rangueil,
Centre Eugène Marquis,
AMU,
Institut Claudius Regaud,
Institut Curie
Funder: Institut National du Cancer Project Code: INCa-DGOS-3718
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder
assignment_turned_inProjectPartners:Centre François Baclesse, Centre Léon Bérard, Institut Bergonié, Hôpital Saint-Louis, Institut Curie +6 partners
Centre François Baclesse,
Centre Léon Bérard,
Institut Bergonié,
Hôpital Saint-Louis,
Institut Curie,
Centre Hospitalier Universitaire de Rouen,
HUS,
Institut de cancérologie Lucien Neuwirth,
Institut Paoli-Calmettes- (IPC),
Institut Claudius Regaud,
Institut Gustave Roussy
Funder: Institut National du Cancer Project Code: INCa-DGOS-3712
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.
assignment_turned_inProjectPartners:Institut Gustave Roussy, Centre Georges-François Leclerc, Institut Claudius Regaud, Institut Curie
Institut Gustave Roussy,
Centre Georges-François Leclerc,
Institut Claudius Regaud,
Institut Curie
Funder: Institut National du Cancer Project Code: INCa-DGOS-5535
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.
assignment_turned_inProject2011 - 2014Partners:Institut Claudius Regaud, INSERM U563
Institut Claudius Regaud,
INSERM U563
Funder: Institut National du Cancer Project Code: INCa-4010
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET
assignment_turned_inProjectPartners:CHUG, Institut Gustave Roussy, Institut Claudius Regaud, CHU, CHU Marseille - Hôpital la Timone +4 partners
CHUG,
Institut Gustave Roussy,
Institut Claudius Regaud,
CHU,
CHU Marseille - Hôpital la Timone,
Hôpital Claude Huriez,
Hôpital Louis Pradel,
Hôpital Haut-Lévêque,
Hôpital Beaujon
Funder: Institut National du Cancer Project Code: INCa-DGOS-5588
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

Institut Claudius Regaud

Institut Claudius Regaud

74 Projects, page 1 of 15

Prospective construction and validation of a prognostic score to idendify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival.

Randomized phase III study of gemcitabine and cisplatin (GC) versus high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder

Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.

Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.

Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET

Loading